12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Infinity, Mundipharma preclinical data

In mice, once-daily 40 mg/kg oral IPI-926 for 5 days significantly inhibited tumor growth of primary patient-derived chondrosarcoma tumor xenografts by an average of 43% vs. vehicle-treated...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >